Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement

Miguel Regueiro, Edward Vincent Loftus, Jr, A. Hillary Steinhart, Russell D. Cohen

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

There are few published guidelines for the treatment of inflammatory bowel disease. Physicians choose therapy based on evidence-based data, peer and expert opinion, and personal experience. This article provides treatment guidelines for the induction and maintenance of ulcerative proctitis and left-sided colitis and the management of disease refractory to 5-aminosalicylic acid (5-ASA) compounds and corticosteroids The guidelines are derived from evidence-based data and, when lacking, expert opinion or the authors' experience. The comprehensive review of the literature is presented in the accompanying article, "The Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis: Critical Evaluation of Therapeutic Trials". Rectally administered 5-ASA and corticosteroid suppositories are effective treatment for most ulcerative proctitis patients. Corticosteroid and 5-ASA enemas, which reach the splenic flexure of the colon, are recommended for patients with left-sided ulcerative colitis. The combination of rectally administered 5-ASA enemas and oral 5-ASA agents may afford better treatment of left-sided colitis and possibly prevent proximal extension of disease. Patients refractory to 5-ASAs and corticosteroids may require an immunomodulator or biological response modifier therapy. Those who have ongoing signs and symptoms of ulcerative proctitis and left-sided ulcerative colitis despite maximal medical therapy require a proctocolectomy.

Original languageEnglish (US)
Pages (from-to)972-978
Number of pages7
JournalInflammatory Bowel Diseases
Volume12
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Proctitis
Ulcerative Colitis
Mesalamine
Guidelines
Adrenal Cortex Hormones
Enema
Expert Testimony
Immunologic Factors
Colitis
Therapeutics
Transverse Colon
Suppositories
Disease Management
Inflammatory Bowel Diseases
Signs and Symptoms
Colon
Maintenance
Physicians

Keywords

  • 5-aminosalicylates
  • Corticosteriods
  • Immunomodulators
  • Infliximab
  • Left-sided ulcerative colitis
  • Medical management
  • Medical treatment
  • Ulcerative colitis
  • Ulcerative proctitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis : Summary statement. / Regueiro, Miguel; Loftus, Jr, Edward Vincent; Steinhart, A. Hillary; Cohen, Russell D.

In: Inflammatory Bowel Diseases, Vol. 12, No. 10, 10.2006, p. 972-978.

Research output: Contribution to journalReview article

@article{3f4efeb805ce4e0f8306e685005fe4e3,
title = "Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement",
abstract = "There are few published guidelines for the treatment of inflammatory bowel disease. Physicians choose therapy based on evidence-based data, peer and expert opinion, and personal experience. This article provides treatment guidelines for the induction and maintenance of ulcerative proctitis and left-sided colitis and the management of disease refractory to 5-aminosalicylic acid (5-ASA) compounds and corticosteroids The guidelines are derived from evidence-based data and, when lacking, expert opinion or the authors' experience. The comprehensive review of the literature is presented in the accompanying article, {"}The Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis: Critical Evaluation of Therapeutic Trials{"}. Rectally administered 5-ASA and corticosteroid suppositories are effective treatment for most ulcerative proctitis patients. Corticosteroid and 5-ASA enemas, which reach the splenic flexure of the colon, are recommended for patients with left-sided ulcerative colitis. The combination of rectally administered 5-ASA enemas and oral 5-ASA agents may afford better treatment of left-sided colitis and possibly prevent proximal extension of disease. Patients refractory to 5-ASAs and corticosteroids may require an immunomodulator or biological response modifier therapy. Those who have ongoing signs and symptoms of ulcerative proctitis and left-sided ulcerative colitis despite maximal medical therapy require a proctocolectomy.",
keywords = "5-aminosalicylates, Corticosteriods, Immunomodulators, Infliximab, Left-sided ulcerative colitis, Medical management, Medical treatment, Ulcerative colitis, Ulcerative proctitis",
author = "Miguel Regueiro and {Loftus, Jr}, {Edward Vincent} and Steinhart, {A. Hillary} and Cohen, {Russell D.}",
year = "2006",
month = "10",
doi = "10.1097/01.mib.0000231496.92013.85",
language = "English (US)",
volume = "12",
pages = "972--978",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis

T2 - Summary statement

AU - Regueiro, Miguel

AU - Loftus, Jr, Edward Vincent

AU - Steinhart, A. Hillary

AU - Cohen, Russell D.

PY - 2006/10

Y1 - 2006/10

N2 - There are few published guidelines for the treatment of inflammatory bowel disease. Physicians choose therapy based on evidence-based data, peer and expert opinion, and personal experience. This article provides treatment guidelines for the induction and maintenance of ulcerative proctitis and left-sided colitis and the management of disease refractory to 5-aminosalicylic acid (5-ASA) compounds and corticosteroids The guidelines are derived from evidence-based data and, when lacking, expert opinion or the authors' experience. The comprehensive review of the literature is presented in the accompanying article, "The Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis: Critical Evaluation of Therapeutic Trials". Rectally administered 5-ASA and corticosteroid suppositories are effective treatment for most ulcerative proctitis patients. Corticosteroid and 5-ASA enemas, which reach the splenic flexure of the colon, are recommended for patients with left-sided ulcerative colitis. The combination of rectally administered 5-ASA enemas and oral 5-ASA agents may afford better treatment of left-sided colitis and possibly prevent proximal extension of disease. Patients refractory to 5-ASAs and corticosteroids may require an immunomodulator or biological response modifier therapy. Those who have ongoing signs and symptoms of ulcerative proctitis and left-sided ulcerative colitis despite maximal medical therapy require a proctocolectomy.

AB - There are few published guidelines for the treatment of inflammatory bowel disease. Physicians choose therapy based on evidence-based data, peer and expert opinion, and personal experience. This article provides treatment guidelines for the induction and maintenance of ulcerative proctitis and left-sided colitis and the management of disease refractory to 5-aminosalicylic acid (5-ASA) compounds and corticosteroids The guidelines are derived from evidence-based data and, when lacking, expert opinion or the authors' experience. The comprehensive review of the literature is presented in the accompanying article, "The Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis: Critical Evaluation of Therapeutic Trials". Rectally administered 5-ASA and corticosteroid suppositories are effective treatment for most ulcerative proctitis patients. Corticosteroid and 5-ASA enemas, which reach the splenic flexure of the colon, are recommended for patients with left-sided ulcerative colitis. The combination of rectally administered 5-ASA enemas and oral 5-ASA agents may afford better treatment of left-sided colitis and possibly prevent proximal extension of disease. Patients refractory to 5-ASAs and corticosteroids may require an immunomodulator or biological response modifier therapy. Those who have ongoing signs and symptoms of ulcerative proctitis and left-sided ulcerative colitis despite maximal medical therapy require a proctocolectomy.

KW - 5-aminosalicylates

KW - Corticosteriods

KW - Immunomodulators

KW - Infliximab

KW - Left-sided ulcerative colitis

KW - Medical management

KW - Medical treatment

KW - Ulcerative colitis

KW - Ulcerative proctitis

UR - http://www.scopus.com/inward/record.url?scp=33749338666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749338666&partnerID=8YFLogxK

U2 - 10.1097/01.mib.0000231496.92013.85

DO - 10.1097/01.mib.0000231496.92013.85

M3 - Review article

C2 - 17012968

AN - SCOPUS:33749338666

VL - 12

SP - 972

EP - 978

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -